Laura Fabbri

Prophylactic or Early Selective Surfactant Combined With nCPAP in Very Preterm Infants

Fabrizio Sandri, Richard Plavka, Gina Ancora et al. · PEDIATRICS · 2010 · 346 citations

Chronic Pulmonary Insufficiency of Prematurity: Developing Optimal Endpoints for Drug Development

Robin H. Steinhorn, Jonathan M. Davis, Wolfgang Göpel et al. · The Journal of Pediatrics · 2017 · 136 citations

Asthma, Optimal Endpoints, Pediatrics +9

A first-in-human clinical study of a new SP-B and SP-C enriched synthetic surfactant (CHF5633) in preterm babies with respiratory distress syndrome

David G. Sweet, M. Turner, Zbyněk Straňák et al. · Archives of Disease in Childhood Fetal & Neonatal · 2017 · 71 citations · Full text

Synthetic Surfactant CHF5633 Compared with Poractant Alfa in the Treatment of Neonatal Respiratory Distress Syndrome: A Multicenter, Double-Blind, Randomized, Controlled Clinical Trial

Rangasamy Ramanathan, Manoj Biniwale, Krishnamurthy Sekar et al. · The Journal of Pediatrics · 2020 · 43 citations

Acute Lung Injury, Neonatology, Controlled Clinical Trial +7

CHF3381, a N-methyl-D-aspartate Receptor Antagonist and Monoamine Oxidase–A Inhibitor, Attenuates Secondary Hyperalgesia in a Human Pain Model

Ole Mathiesen, Bruno P. Imbimbo, Karen Lisa Hilsted et al. · Journal of Pain · 2006 · 38 citations

Pain Therapy, Pain Syndrome, Pain Disorders +15